Understand the source comparison
Top Selling Peptides June 2026: Research Application Comparison
The following table categorizes the top selling peptides June 2026 by primary research application, mechanism class, and key published evidence driving current demand. Tirzepatide Dual GIP/GLP-1 agonist Metabolic disease, MASLD, cardiovascular risk reduction S
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table categorizes the top selling peptides June 2026 by primary research application, mechanism class, and key published evidence driving current demand.
- Tirzepatide
- Dual GIP/GLP-1 agonist
- Metabolic disease, MASLD, cardiovascular risk reduction
- SURPASS trials: 22.5% weight reduction, 2.58% HbA1c reduction at 72 weeks
- 5–15mg weekly (subcutaneous)
- Retatrutide
- Triple GIP/GLP-1/glucagon agonist
- Obesity research, metabolic adaptation prevention
- Phase 2 trial: 24.2% weight reduction at 48 weeks, highest pharmacological result to date
- 8–12mg weekly (subcutaneous)
- BPC-157
- Angiogenic, cytoprotective
- Tendon/ligament repair, gastric ulcer healing, addiction models
- Preclinical models: accelerated tendon healing timelines, VEGF upregulation
- 200–500mcg daily (subcutaneous or oral)
- Survodutide
- Dual GLP-1/glucagon agonist
- NASH/MASLD, liver fibrosis reversal
- Phase 2: 74% achieved ≥30% liver fat reduction at 26 weeks
- 2.4–4.8mg weekly (subcutaneous)
- TB-500
- Actin-regulating, anti-inflammatory
- Wound healing, cardiac repair, traumatic brain injury
- Preclinical: reduced fibrosis in cardiac injury, improved TBI functional recovery
- 2–5mg twice weekly (subcutaneous)
- Dihexa
- HGF receptor agonist, BDNF potentiator
- Alzheimer's models, cognitive enhancement, stroke recovery
- Preclinical: cognitive deficit reversal in AD models, synaptogenesis promotion
- 1–10mg daily (oral or subcutaneous). Human data limited